https://quetzaltx.com/press/ 2026-06-18T15:02:41+00:00 https://quetzaltx.com/press/quetzal-therapeutics-debuts-with-expert-leadership-high-impact-pipeline-and-50-million-of-committed-capital/ 2026-05-05T19:08:08+00:00 https://quetzaltx.com/press/quetzal-therapeutics-appoints-dr-shaad-abedin-as-chief-medical-officer/ 2026-05-05T19:08:34+00:00 https://quetzaltx.com/press/quetzal-therapeutics-appoints-todd-smith-as-board-member/ 2026-05-05T19:10:57+00:00 https://quetzaltx.com/press/quetzal-therapeutics-launches-phase-iii-clinical-trial-of-oral-qtx-2101-for-acute-promyelocytic-leukemia-apl/ 2026-05-05T19:13:50+00:00 https://quetzaltx.com/press/qtx-2101-awarded-fda-fast-track-designation-for-the-treatment-of-acute-promyelocytic-leukemia/ 2026-05-05T19:19:02+00:00 https://quetzaltx.com/press/quetzal-therapeutics-announces-first-patient-dosed-in-phase-3-quatro-apl-trial-of-qtx-2101-for-frontline-acute-promyelocytic-leukemia/ 2026-06-18T15:02:41+00:00